Headlines about Intercept Pharmaceuticals (NASDAQ:ICPT) have been trending somewhat positive on Thursday, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intercept Pharmaceuticals earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.7500411897064 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Several brokerages recently weighed in on ICPT. Royal Bank of Canada cut Intercept Pharmaceuticals from an “outperform” rating to a “sector perform” rating and set a $244.00 target price for the company. in a research note on Wednesday, August 15th. They noted that the move was a valuation call. Wedbush set a $217.00 target price on Intercept Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, August 12th. Zacks Investment Research cut Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 7th. Goldman Sachs Group raised Intercept Pharmaceuticals from a “sell” rating to a “buy” rating and raised their target price for the company from $46.00 to $157.00 in a research note on Monday, August 6th. Finally, Laidlaw cut Intercept Pharmaceuticals from a “buy” rating to a “hold” rating and raised their target price for the company from $90.00 to $95.00 in a research note on Friday, August 3rd. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company’s stock. Intercept Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $123.81.
NASDAQ:ICPT opened at $111.76 on Thursday. The company has a debt-to-equity ratio of 2.48, a current ratio of 6.51 and a quick ratio of 6.51. Intercept Pharmaceuticals has a 1-year low of $51.05 and a 1-year high of $119.47. The firm has a market capitalization of $3.31 billion, a P/E ratio of -7.77 and a beta of -1.72.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($2.58) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($2.83) by $0.25. Intercept Pharmaceuticals had a negative return on equity of 614.15% and a negative net margin of 215.30%. The business had revenue of $43.58 million during the quarter, compared to analyst estimates of $41.26 million. During the same quarter last year, the company posted ($3.46) EPS. Intercept Pharmaceuticals’s revenue for the quarter was up 41.1% on a year-over-year basis. research analysts expect that Intercept Pharmaceuticals will post -10.86 EPS for the current fiscal year.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).
Featured Story: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.